Investment & funding
A French biotech has raised €12m to test whether GLP-1 drugs can modify osteoarthritis progression. The funding will advance 4Moving Biotech's lead programme, 4P004, toward a phase 2a proof-of-concept readout in knee osteoarthritis, a joint disease that causes pain and stiffness. Despite affecting more than 600 million people worldwide, no therapy approved in Europe or [...]
Harbor Health has acquired dementia care startup Rippl; terms were not disclosed. Founded in 2021, Rippl provides specialised dementia care and support, including personalised care plans, medication assessments and 24/7 access to care navigators and licensed clinicians. The Seattle-based company aims to help seniors with dementia stay at home and reduce emergency department visits. It [...]
Longevity startup Biopeak has secured US$2.7m in a follow-on funding round. Founded in 2025 by Rishi Pardal and Shiva Subramanian, Biopeak operates India’s first specialised brand aimed at extending lifespans through preventive care. The company opened a clinic in Bengaluru last year and plans to open a second one in the coming month. The funds [...]
Biotechnology company Aerska has raised US$39m in Series A funding to develop brain-delivered RNA medicines. The company is developing treatments for neurological diseases, including genetically driven forms of Alzheimer's disease. This takes Aerska's total funding to US$60m, months after its seed funding announcement in October 2025. The company's platform uses what it calls "brain shuttle" [...]
Longevity startup Biopeak has secured US$2.7m in a follow-on round led by NKSquared, the investment vehicle of Zerodha co-founder Nikhil Kamath. This is Kamath's second investment in the company after he put US$1.43m into the health optimisation startup in August 2024. Founded in 2025 by Rishi Pardal and Shiva Subramanian, Biopeak operates India’s first specialised [...]
NewLimit has secured an extra US$45m on a US$1.62bn valuation to advance epigenetic reprogramming medicines and prepare for a first clinical study in the coming years. The company is developing therapies to restore youthful function in older cells. Epigenetic reprogramming aims to reset chemical “tags” on DNA and its packaging proteins, restoring healthier gene activity [...]
